drugset / Trial / NCT01788137
A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients
Phase 3
Unknown
380 enrolled
Sun Yat-sen University
Chinese Academy of Medical Sciences · collabFudan University · collabTianjin Medical University Cancer Institute and Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective , open, multicenter, randomized phase III study. The investigators planed to include 380 untreated high risk T cell lymphoma adults,to random to CHOP and c-ATT regimen groups after signature the informed consents. The patients will receive safety assessment every cycles, and efficacy evaluation every 3 cycles. Every-two-months follow up will be received after finishing the treatment.
Timeline
- Start
- 2008-01
- Primary completion
- 2017-04
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Comparator | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Comparator | Prednisone | Other / unclassified | 60 mg/m2 | Oral |
| Comparator | Vincristine | Small molecule | 1.4 mg/m2 | — |